M&A Deal Summary

Sumitovant Biopharma Acquires Urovant Sciences

On November 12, 2020, Sumitovant Biopharma acquired life science company Urovant Sciences for 584M USD

Acquisition Highlights
  • This is Sumitovant Biopharma’s 1st transaction in the Life Science sector.
  • This is Sumitovant Biopharma’s largest (disclosed) transaction.
  • This is Sumitovant Biopharma’s 1st transaction in the United States.
  • This is Sumitovant Biopharma’s 1st transaction in California.

M&A Deal Summary
Date 2020-11-12
Target Urovant Sciences
Sector Life Science
Buyer(s) Sumitovant Biopharma
Deal Type Add-on Acquisition
Deal Value 584M USD
Advisor(s) Lazard Ltd. (Financial)
O'Melveny & Myers (Legal)

Target

Urovant Sciences

Irvine, California, United States
Urovant Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions. Urovant Sciences is based in Irvine, California.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Sumitovant Biopharma

New York, New York, United States
Category Company
Sector Life Science
DESCRIPTION

Sumitovant Biopharma, Inc. is a global biopharmaceutical company. Sumitovant Biopharma is based in New York.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (California) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal